Concise Account Of Pradaxa Lawsuits

Pradaxa (dabigatran) is an anticoagulant which is also called a thrombin inhibitor and is used for preventing the formation of blood clots in the body. Manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., one of the biggest pharmaceutical companies in the world, the drug was approved by the Food and Drug Administration (FDA) in 2010.

Unfortunately, this blood thinner received a lot of negative reports most of which was about the risk of uncontrollable bleeding. Boehringer Ingelheim Pharmaceuticals received as many as 2,400 Pradaxa lawsuits soon after the drug was released. The victims claim for pradaxa lawsuit settlement for the undue pain and suffering they had to face from this drug.

Complications noted in the lawsuit

Being a blood thinner, the major problem with the drug was about the risk of unstoppable bleeding as there was no known antidote till 2015. 

The following are some of the side effects of the drug that has been commonly reported by the patients:

• ·          Unusual bleeding or bruising
• ·         Coughing up blood
• ·         Chest tightness or pain
• ·         Swelling of some body parts
• ·         Dizziness or feeling faint
• ·         Weakness
• ·         Hives, rash, or itching
• ·         Nausea
• ·         Pink or brown urine
• ·         Upset stomach
• ·         Headache
• ·         Stomach pain
• ·         Heartburn

What are the main accusations?

According to the allegations in the lawsuit, Boehringer Ingelheim has no known antidote for the drug and they did not seek approval for it until 2015. There are further claims in the lawsuits which state how the manufacturer misled and misbranded the patients and their physicians about the risks and benefits linked with the drug. The victims claim for the expenses of their medical treatment, pain and losses in pradaxa lawsuit settlement as the manufacturer involved itself in deceptive marketing practices.

Settlement in Pradaxa

As of today, there is no known Pradaxa class action lawsuit but the lawyers have received individual personal injury cases. On May 28, 2014, Boehringer Ingelheim announced for a settlement of worth $650 million which would pay off over 4000 lawsuits pending at that time.